top of page

Search

PATENT NEWS

Mar 13, 20231 min read

GB2582571A describing SYNTHERIX unique Coumarin / Naphthalene/ Arginine warhead is at present in PCT in Europe and the USA.

A new patent specifically claiming ONKONEK (HILR-056)SYNTHERIX lead agent is presently being filed.

Recent Posts

The patent describing ONKONEK's unique cancer-killing warhead has just been granted in Europe.

The patent describing ONKONEK's unique cancer-killing warhead has just been granted in Europe.

Selectively depleting the energy of cancer cells: A new therapeutic paradigm

Selectively depleting the energy of cancer cells: A new therapeutic paradigm

ESSENTIAL MOLECULAR

ESSENTIAL MOLECULAR

Comments

bottom of page